Objectives: At present, the dose conversion ratio for a continuous intravenous infusion of fentanyl (CIV) and fentanyl transdermal patches (TP), which are widely used in Japan, is not based on the results of clinical studies in Japanese patients. Studies comparing serum fentanyl concentrations in patients with cancer pain treated by TP showed large differences between Japanese patients and those in other countries. We therefore studied the dose conversion ratio in Japanese patients. Methods: From October 2003 through October 2008, we extracted information on all patients with gastrointestinal cancer who underwent rotation from CIV to TP in the gastrointestinal ward of Kitasato University East Hospital. We selected patients in whom the daily dose of CIV or TP (i.e., the basic dose) was unchanged for 10 days after rotation and the difference in the number of rescue doses (per day) as compared with immediately before rotation was 1 or less on at least 3 consecutive days. All TP preparations used in this study were reservoir-type. Regression lines were plotted on the basis of the relation of "the basic released dose of TP" to "the basic prescribed dose of CIV," and the dose conversion ratio was calculated. Results: 47 patients underwent opioid rotation, and 11 of them satisfied the eligibility criteria. Eleven patients were studied. The following regression equation was obtained: Y＝1.0227X＋1.0103, r 2 ＝0.9188, indicating a strong correlation. The dose conversion ratio of CIV to TP (released dose) derived by regression analysis was 1:1. Conclusions: Our results obtained in Japanese patients will allow dose conversion at the time of opioid rotation from CIV to TP to be more appropriately performed. Palliat Care Res 2012; 7(2): 218-24
Introduction
The concept of "opioid rotation" has been advocated for the treatment of cancer pain and is defined as "switching from one opioid to another with the aim of achieving a better response." Actually, opioid rotation refers to changing the route of administration or switching to another opioid preparation because of uncontrollable side effects, inadequate analgesia even at an increased dose, inability to orally administer a preparation, or other factors 1) .
At the time of opioid rotation, changes in factors such as the type of opioid, dosage form, or route of administration necessitate dose adjustment to obtain an equivalent level of analgesic efficacy. It is therefore important to establish dose equivalency among different opioid preparations, and dose equivalency ratios for various preparations have been reported [2] [3] [4] [5] [6] [7] [8] .
On opioid rotation from continuous intravenous infusion of fentanyl (fentanyl CIV) to fentanyl transdermal patch (fentanyl TP), dose conversion can be based on the bioavailability of fentanyl TP because the active ingredient is the same. The interview forms for Durotep ® patch, a fentanyl reservoir−type formulation of fentanyl TP, and Durotep ® MT patch, a matrix formulation of fentanyl TP, state that the bioavailability is 0.92. However, in the clinical study (8 patients) that was the source of this value, bioavailability widely ranged from 0.70 to 1.46 and exceeded 1.0 in 2 patients 9) . These findings suggested that the bioavailability in that clinical study might have been overestimated owing to some factor(s). Therefore, it may not be appropriate to directly use the bioavailability obtained in that study for dose conversion.
In clinical practice, a dose conversion ratio of 1:1 has been used for switching from fentanyl CIV to fentanyl TP on the basis of the results of a study conducted by Grond, et al 10) . However, this ratio was not derived from the results of clinical studies in Japanese patients. The summary basis of approval for Durotep ® patch 11) reported substantial differences in serum fentanyl concentrations between Japanese patients with cancer pain and patients with cancer pain in other countries. To our knowledge, dose conversion ratios for fentanyl CIV and fentanyl TP have not been clinically studied previously in Japanese patients. We therefore examined dose conversion ratios in Japanese patients with cancer pain who underwent opioid rotation from fentanyl CIV to fentanyl TP.
Methods 1 Patients
From , we selected patients in whom the daily dose of fentanyl CIV or fentanyl TP (i.e., the basic dose) was unchanged for 10 days after rotation and the difference in the number of rescue doses (per day) as compared with immediately before rotation was 1 or less on at least 3 consecutive days. All fentanyl TP preparations used in our study were reservoir−type. Our study was performed after approval had been obtained from the Ethics Review Board of Kitasato University Hospital.
Variables
The following information was obtained from the patients' medical As for the use of opioids, the basic doses and the numbers of rescue doses (per day) of fentanyl CIV and fentanyl TP were surveyed from immediately before rotation until 10 days after rotation. Given that 2.5 mg/3 days of reservoir−type fentanyl TP is equivalent to a released dose of 0.6 mg/day of fentanyl 12) , the daily released dose (basic released dose) was calculated from the basic prescribed dose of fentanyl TP. 
Results
During the study period, 47 patients underwent opioid rotation from fentanyl CIV to fentanyl TP. In 11 of these patients, the basic dose of fentanyl CIV or fentanyl TP was unchanged for 10 days after opioid rotation and the difference in the daily number of rescue doses was 1 or less on at least 3 consecutive days as compared with immediately before rotation. Reservoir−type Durotep ® fentanyl patches were used as fentanyl TP in all patients. The patients' demographic characteristics are shown in Table 1 . Table 2 shows the serum chemical values immediately before opioid rotation.
In the 11 selected patients, the median basic prescribed dose of fentanyl CIV was 0.5 mg (range, 0.4 to 2.4), and the median basic released dose of fentanyl TP was 0.6 mg (range, 0.3 to 2.4). 
Discussion
Fentanyl is a potent opioid with high affinity for the μ 1 −opioid receptor and low affinity for the μ 2 −opioid receptor. It is about 100 times more potent than morphine. As compared with morphine and oxycodone, fentanyl is associated with lower incidences of side effects such as constipation, vomiting, and drowsiness 4)
. Moreover, the main metabolite of fentanyl, norfentanyl, has virtually no pharmacologic activity and thus does not augment pharmacologic effects in patients with decreased renal function, in contrast to morphine−6−glucuronide, a metabolite of morphine. Fentanyl can be therefore easy to use in patients with compromised renal function 13, 14) . Fentanyl has a low molecular weight and is highly lipophilic, allowing it to be delivered by a transdermal patch. Fentanyl TP is superior to other opioid preparations because it is simple and noninvasive, with a long duration of action 12, 15) . Because many patients with terminal cancer have difficulty in oral intake, fentanyl TP offers substantial advantages 16) . Owing to these characteristics, fentanyl TP plays a very important role in clinical practice. We thus consider it very meaningful to study opioid rotation from fentanyl CIV to fentanyl TP and thereby promote the appropriate use of these preparations.
In our study, the dose conversion ratio was based on response within the first 10 days after opioid rotation. Patients who had increased pain intensity caused by exacerbation of underlying disease were therefore excluded. In addition, the dose conversion ratio was calculated on the basis of data from patients in whom the basic prescribed dose was unchanged and the difference in the number of rescue doses (per day) as compared with immediately before rotation was 1 or less on at least 3 consecutive days.
Fentanyl injection was most commonly used to supply rescue doses, followed by oral solution and suppositories of morphine hydrochloride and oxycodone hydrochloride powder. If fentanyl CIV was used as the basic prescribed drug, fentanyl was given as a rapid intra-venous infusion at a dose equivalent to 1/24 to 1/12 of the basic prescribed dose for rescue treatment. If fentanyl TP was used as the basic prescribed drug, fentanyl was given orally or in suppository form in a dose equivalent to 1/6 to 1/4 of the basic prescribed dose (released dose) or by intravenous injection in a dose equivalent to 1/12 to 1/6 of the basic prescribed dose (released dose). In our hospital, rescue doses are prescribed at the same time as basic prescribed drugs, and patients can take rescue doses any time they feel pain. All subjects in our study were prescribed rescue doses. Therefore, the use of rescue doses is considered a clinical indicator that most strongly reflects pain experienced by the patient. The use of rescue doses in patients with a low basic prescribed dose may be reflected in the basic prescribed dose on the next day (i.e., as a dose increase). A high basic prescribed dose often leads to side effects such as drowsiness, leading to modification of (i.e., a decrease in) the basic prescribed dose from the next day.
Eleven patients who met the protocol requirements were selected for this study. Creatinine clearance was estimated with the Cockcroft-Gault equation.
AST; aspartate aminotransferase, ALT; alanine aminotransferase. NSAIDs; nonsteroidal anti-inflammatory drugs.
The concurrent use of nonopioid analgesics may augment analgesic effects, decreasing the required dose of opioids 17) . Nine of our 11 patients concurrently used analgesics other than opioids. All patients had continuously received these analgesics from before the start of opioid rotation, and the drugs and dosage used were not altered. The effect of concomitant analgesics on the dose conversion ratio calculated in our study was thus considered minimal.
Of the 11 subjects, 3 had grade 3 abnormalities on serum blood .9063, indicating a strong correlation and no effect on the dose conversion ratio.
All fentanyl TP preparations used in our study were reservoir−type.
A comparative study of the pharmacokinetic parameters calculated on the basis of serum fentanyl concentrations after treatment with reservoir−type and matrix−type preparations showed that these two preparations are bioequivalent 20) . We therefore believe that the dose conversion ratio obtained in our study can be used for matrix−type preparations.
The dose conversion ratio for opioid rotation from fentanyl CIV to fentanyl TP currently used in Japan is based on the results of a study conducted by Grond, et al 10) . Their study did not include Japanese patients. The summary basis of approval of Durotep ® patch 11) reported a large difference in serum fentanyl concentrations between Japanese patients with cancer pain and those from other countries. Our study clarified the dose conversion ratio for opioid rotation from fentanyl CIV to fentanyl TP in Japanese patients with cancer pain. On the basis of Japanese data, dose conversion at the time of opioid rotation from fentanyl CIV to fentanyl TP can be appropriately performed, contributing to improvement in patients' quality of life.
Because our study was retrospective, pain intensity at the time of using rescue doses was not examined. As mentioned above, rescue doses are prescribed at the same time as basic prescribed drugs in our hospital, and patients can take rescue doses whenever they feel pain.
Therefore, the number of rescue doses used is considered a clinical index that most closely reflects patients' pain. Future studies should further assess pain intensity before and after opioid rotation, as well as the types and numbers of rescue doses used. 
